APA

Gebhart G., Lamberts L. E., Wimana Z., Garcia C., Emonts P., Ameye L., Stroobants S., Huizing M., Aftimos P., Tol J., Oyen W. J. G., Vugts D. J., Hoekstra O. S., Schröder C. P., Menke-van der Houven van Oordt C. W., Guiot T., Brouwers A. H., Awada A., de Vries E. G. E. & Flamen P. (20161213). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Gebhart G, Lamberts L E, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen W J G, Vugts D J, Hoekstra O S, Schröder C P, Menke-van der Houven van Oordt C W, Guiot T, Brouwers A H, Awada A, de Vries E G E and Flamen P. 20161213. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Gebhart G., Lamberts L. E., Wimana Z., Garcia C., Emonts P., Ameye L., Stroobants S., Huizing M., Aftimos P., Tol J., Oyen W. J. G., Vugts D. J., Hoekstra O. S., Schröder C. P., Menke-van der Houven van Oordt C. W., Guiot T., Brouwers A. H., Awada A., de Vries E. G. E. and Flamen P. (20161213). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Gebhart G, Lamberts L E, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen W J G, Vugts D J, Hoekstra O S, Schröder C P, Menke-van der Houven van Oordt C W, Guiot T, Brouwers A H, Awada A, de Vries E G E and Flamen P. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. : Annals of oncology : official journal of the European Society for Medical Oncology. 20161213.